ArticleJournal of gastrointestinal oncology2025
Real-world effectiveness of anamorelin in patients with unresectable and relapse pancreatic cancer: a prospective observational study.
Article in Journal of gastrointestinal oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Beyond Hunger: The Structure, Signaling, and Systemic Roles of Ghrelin.International journal of molecular sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Anamorelin, a ghrelin receptor agonist, has recently been used to treat cachexia in patients with pancreatic cancer (PC). Although it was accepted in Japan for advanced PC for the first time in the world in 2020, its efficacy and safety were not fully tested. Thus, we sought to determine the safety and efficacy of anamorelin in patients with inoperable and relapsed PC. Methods: We prospectively enrolled patients with inoperable and relapsed PC who had started anamorelin, lost their appetite, and met the criteria for cachexia. Appetite, body weight (BW), and muscle weight were measured at 0, 1, 2, 3, and 4 months. Characteristics and survival rates were compared between those who demonstrated anamorelin efficacy and those who did not. Results: Out of the 45 patients studied, 31 continued anamorelin for 1 month and 20 for 4 months. After 1 month, appetite improved significantly (+1, range 0-4, P<0.001). BW (+1.8 kg, IQR 0.13-3.08, P<0.05) and muscle weight (+0.9 kg, IQR -0.05-2.6, P<0.05) showed significant increases. At 4 months, the increase in appetite, BW, and muscle weight remained stable. Patients who showed anamorelin effectiveness lived significantly longer than those who did not (366 Conclusions: In inoperable and relapsed PC, anamorelin may be more effective in patients with a better overall condition and is associated with longer survival. To improve patient outcomes, appetite and BW must be monitored regularly and anamorelin treatment should begin early.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.